B cells in renal transplantation: Pathological aspects and therapeutic interventions

Nephrology Dialysis Transplantation

Volumn 26, Issue 3, 2011, Pages 767-774

  Barnett, Nicholas ^a   Dorling, Anthony ^a   Mamode, Nizam ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

B lymphocytes; Graft rejection; Humoral; Immunity

Indexed keywords

ALEMTUZUMAB; ANTIBODY; ATACICEPT; B CELL ACTIVATING FACTOR; BORTEZOMIB; COMPLEMENT COMPONENT C4D; DACLIZUMAB; ECULIZUMAB; IMMUNOGLOBULIN G; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CHRONIC GRAFT REJECTION; CYTOARCHITECTURE; CYTOKINE PRODUCTION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; INFECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; MEMORY CELL; PATHOLOGY; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPLENECTOMY; T CELL MEDIATED REJECTION; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ANIMALS; B-LYMPHOCYTES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION;

EID: 79952151944     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq716     Document Type: Article

References (78)

1. Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001;13:195-201 (Pubitemid 32176039)
2. von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010;11:14-20
3. Montecino-Rodriguez E, Dorshkind K. New perspectives in B-1B cell development and function. Trends Immunol 2006;27:428-433 (Pubitemid 44216193)
4. Paus D, Phan TG, Chan TD et al. Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. J Exp Med 2006;203:1081-1091
5. Murphy K, Travers P, Walport M. Janeway's Immunobiology. 7th edn Oxford: Garland Science, 2008
6. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006;18:263-275 (Pubitemid 44287558)
7. Mackay F, Figgett WA, Saulep D et al. B-cell stage and contextdependent requirements for survival signals from BAFF and the B-cell receptor. Immunol Rev 2010;237:205-225
8. Avery DT, Deenick EK, Ma CS et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010;207:155-171
9. Moser K, Tokoyoda K, Radbruch A et al. Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol 2006;18:265-270
10. Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006;6:107-116 (Pubitemid 43361586)
11. Thaunat O, Patey N, Morelon E et al. Lymphoid neogenesis in chronic rejection: the murderer is in the house. Curr Opin Immunol 2006;18:576-579 (Pubitemid 44311452)
12. Kerjaschki D, Regele HM, Moosberger I et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004;15:603-612 (Pubitemid 38294790)
13. Youinou P. B cell conducts the lymphocyte orchestra. J Autoimmun 2007;28:143-151 (Pubitemid 46670692)
14. Tumanov AV, Kuprash DV, Lagarkova MA et al. Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity 2002;17:239-250 (Pubitemid 35279546)
15. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008;224:201-214
16. Blair PA, Norena LY, Flores-Borja F et al. CD19 (+) CD24 (hi) CD38 (hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010;32:129-140
17. Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens 2007;69:545-556 (Pubitemid 46733686)
18. Noorchashm H, Reed AJ, Rostami SY et al. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 2006;177:7715-7722 (Pubitemid 44846287)
19. Thaunat O, Morelon E, Defrance T. Am"B"valent: anti-CD20 antibodies unravel the dual role of B cells in immunopathogenesis. Blood 2010;116:515-521
20. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004;4:1033-1041 (Pubitemid 38868592)
21. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003;3:708-714 (Pubitemid 36745243)
22. Solez K, Colvin RB, Racusen LC et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007;7:518-526 (Pubitemid 46376465)
23. Zarkhin V, Kambham N, Li L et al. Characterization of intra-graft B cells during renal allograft rejection. Kidney Int 2008;74:664-673
24. Muorah MR, Brogan PA, Sebire NJ et al. Dense B cell infiltrates in paediatric renal transplant biopsies are predictive of allograft loss. Pediatr Transplant 2009;13:217-222
25. Hippen BE, De Mattos A, Cook WJ et al. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005;5:2248-2252 (Pubitemid 41648473)
26. Doria C, di Francesco F, Ramirez CB et al. The presence of B-cell nodules does not necessarily portend a less favorable outcome to therapy in patients with acute cellular rejection of a renal allograft. Transplant Proc 2006;38:3441-3444 (Pubitemid 44908548)
27. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010;15:42-48
28. Xu H, He X, Sun J et al. The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4D in kidney allograft rejection. Transplant Proc 2009;41:112-116
29. Satoskar AA, Lehman AM, Nadasdy GM et al. Peritubular capillary C4d staining in late acute renal allograft rejection - is it relevant? Clin Transplant 2008;22:61-67 (Pubitemid 351150004)
30. Sijpkens YW, Joosten SA, Wong MC et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004;65:2409-2418 (Pubitemid 38670027)
31. Haas M, Rahman MH, Racusen LC et al. C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006;6:1829-1840 (Pubitemid 44024954)
32. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753-760 (Pubitemid 351347767)
33. Sis B, Mengel M, Haas M et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010;10:464-471
34. Sis B, Campbell PM, Mueller T et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007;7:1743-1752 (Pubitemid 46905427)
35. Mao Q, Terasaki PI, Cai J et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a fiveyear longitudinal study. Am J Transplant 2007;7:864-871 (Pubitemid 46481194)
36. Everly MJ, Everly JJ, Arend LJ et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009;9:1063-1071
37. Knechtle SJ, Pascual J, Bloom DD et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009;9:1087-1098
38. Tan HP, Kaczorowski DJ, Basu A et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006;6:2409-2417 (Pubitemid 44359428)
39. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003;3:653-664 (Pubitemid 36745237)
40. Jordan SC, Vo AA, Tyan D et al. Current approaches to treatment of antibody-mediated rejection. Pediatr Transplant 2005;9:408-415 (Pubitemid 40780375)
41. Heidt S, Roelen DL, Eijsink C et al. Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin Exp Immunol 2009;158:99-105
42. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-251 (Pubitemid 352008439)
43. Lefaucheur C, Nochy D, Andrade J et al. Comparison of combination plasmapheresis/IVIg/Anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009;9:1099-1107
44. Slatinska J, Honsova E, Burgelova M et al. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial 2009;13:108-112
45. Tanriover B, Wright SE, Foster SV et al. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transplant Proc 2008;40:3393-3396
46. Zand MS, Vo T, Huggins J et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005;79:1507-1515 (Pubitemid 40847581)
47. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009;9:201-209
48. Shah A, Nadasdy T, Arend L et al. Treatment of C4D-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation 2004;77:1399-1405 (Pubitemid 38668435)
49. van der Kolk LE, Baars JW, Prins MH et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-2259 (Pubitemid 35001266)
50. Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95
51. Genberg H, Hansson A, Wernerson A et al. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006;6:2418-2428 (Pubitemid 44359429)
52. Genberg H, Kumlien G, Wennberg L et al. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 2008;85:1745-1754
53. Tyden G, Genberg H, Tollemar J et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 2009;87:1325-1329
54. van den Hoogen MWF, Hilbrands LB. More on B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009;361:1215-1215
55. Clatworthy MR, Watson CJE, Plotnek G et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med 2009;360:2683-2685
56. Kaposztas Z, Podder H, Mauiyyedi S et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009;23:63-73
57. Billing H, Rieger S, Ovens J et al. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 2008;86:1214-1221
58. Fehr T, Rusi B, Fischer A et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009;87:1837-1841
59. Rostaing L, Guilbeau-Frugier C, Fort M et al. Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int 2009;22:906-913
60. Steinmetz OM, Lange-Husken F, Turner JE et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation 2007;84:842-850 (Pubitemid 351338944)
61. Thaunat O, Patey N, Gautreau C et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008;85:1648-1653
62. Lavie F, Miceli-Richard C, Ittah M et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-703 (Pubitemid 46707145)
63. Winkler U, Jensen M, Manzke O et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224 (Pubitemid 29467667)
64. Kamar N, Milioto O, Puissant-Lubrano B et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010;10:89-98
65. Drage M, Hadjianastassiou V, Dorling A et al. Letter in response to 'Incidence and predictive factors for infectious disease after rituximab therapy in kidney transplant patients'. Am J Transplant 2010; [in press]
66. Obeng EA, Carlson LM, Gutman DM et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-4916 (Pubitemid 43882644)
67. Diwan T, Burns J, Perry D et al. Effect of proteasome inhibition on alloantibody secreting cells in vivo. Am J Transplant 2009;9:241-241
68. Wahrmann M, Haidinger M, Koermoeczi GF et al. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation (Hagerstown) 2010;89:1385-1390
69. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009;87:1555-1561
70. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008;86:1754-1761
71. Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010;89:277-284
72. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010;10:681-686
73. Sawada T, Fuchinoue S, Kawase T et al. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004;18:254-260 (Pubitemid 38744848)
74. Gloor JM, Lager DJ, Fidler ME et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005;80:1572-1577 (Pubitemid 43005868)
75. Locke JE, Zachary AA, Haas M et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007;7:842-846 (Pubitemid 46481192)
76. Kaplan B, Gangemi A, Thielke J et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007;83:99-100 (Pubitemid 46104982)
77. Dall'Era M, Chakravarty E, Wallace D et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum 2007;56:4142-4150
78. Rossi JF, Moreaux J, Hose D et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study. Br J Cancer 2009;101:1051-1058